REDUCE (Reviewing long-term antidepressant use by careful monitoring in everyday practice) internet and telephone support to people coming off long-term antidepressants: protocol for a randomised controlled trial
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Around one in ten adults take antidepressants for depression in England, and their long-term use is increasing. Some need them to prevent relapse, but 30–50% could possibly stop them without relapsing and avoid adverse effects and complications of long-term use. However, stopping is not always easy due to withdrawal symptoms and a fear of relapse of depression. When general practitioners review patients on long-term antidepressants and recommend to those who are suitable to stop the medication, only 6–8% are able to stop. The Reviewing long-term antidepressant use by careful monitoring in everyday practice (REDUCE) research programme aims to identify safe and cost-effective ways of helping patients taking long-term antidepressants taper off treatment when appropriate. Methods: Design: REDUCE is a two-arm, 1:1 parallel group randomised controlled trial, with randomisation clustered by participating family practices. Setting: England and north Wales. Population: patients taking antidepressants for longer than 1 year for a first episode of depression or longer than 2 years for repeated episodes of depression who are no longer depressed and want to try to taper off their antidepressant use. Intervention: provision of ‘ADvisor’ internet programmes to general practitioners or nurse practitioners and to patients designed to support antidepressant withdrawal, plus three patient telephone calls from a psychological wellbeing practitioner. The control arm receives usual care. Blinding of patients, practitioners and researchers is not possible in an open pragmatic trial, but statistical and health economic data analysts will remain blind to allocation. Outcome measures: the primary outcome is self-reported nine-item Patient Health Questionnaire at 6 months for depressive symptoms. Secondary outcomes: depressive symptoms at other follow-up time points, anxiety, discontinuation of antidepressants, social functioning, wellbeing, enablement, quality of life, satisfaction, and use of health services for costs. Sample size: 402 patients (201 intervention and 201 controls) from 134 general practices recruited over 15–18 months, and followed-up at 3, 6, 9 and 12 months. A qualitative process evaluation will be conducted through interviews with 15–20 patients and 15–20 practitioners in each arm to explore why the interventions were effective or not, depending on the results. Discussion: Helping patients reduce and stop antidepressants is often challenging for practitioners and time-consuming for very busy primary care practices. If REDUCE provides evidence showing that access to internet and telephone support enables more patients to stop treatment without increasing depression we will try to implement the intervention throughout the National Health Service, publishing practical guidance for professionals and advice for patients to follow, publicised through patient support groups. Trial registration: ISRCTN:12417565. Registered on 7 October 2019.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Development of a theory of implementation and integration: Normalization Process Theory
May, C. R., Mair, F., Finch, T., MacFarlane, A., Dowrick, C., Treweek, S., Rapley, T., Ballini, L., Ong, B. N., Rogers, A., et al. (2009) · Implementation Science · doi:10.1186/1748-5908-4-29 · Cited by 1,409
Self-citationValuing health-related quality of life: an EQ-5D-5L value set for England
Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2018) · Health Economics · doi:10.1002/hec.3564 · Cited by 1,356
Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153
Antidepressant use and risk of adverse outcomes in older people: population based cohort study
Coupland, C., Dhiman, P., Morriss, R., Arthur, A., Barton, G., & Hippisley-Cox, J. (2011) · BMJ · doi:10.1136/bmj.d4551 · Cited by 833
SSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669
Eldridge, S. M., Ashby, D., & Kerry, S. (2006) · International Journal of Epidemiology · doi:10.1093/ije/dyl129 · Cited by 529
Stewart-Brown, S., Platt, S., Tennant, A., Maheswaran, H., Parkinson, J., Weich, S., Tennant, R., Taggart, F., & Clarke, A. (2011) · Journal of Epidemiology and Community Health · doi:10.1136/jech.2011.143586.86 · Cited by 291
Cited by
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Self-citationThe effects of social group interventions for depression: systematic review
Dingle, G. A., Sharman, L. S., Haslam, C., Donald, M., Turner, C., Partanen, R., Lynch, J., Draper, G., & van Driel, M. L. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.125 · Cited by 54
Read, J., Renton, J., Harrop, C., Geekie, J., & Dowrick, C. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320950124 · Cited by 43
“…(COVID-19), however, with no further recruitment possible, or appropriate, we hoped our data, however limited, may be helpful to government officials, professional bodies, and researchers, 47 planning for implementation of the hugely important PHE Report once these circumstances abate.”
Self-citationCooper, R. E., Ashman, M., Lomani, J., Moncrieff, J., Guy, A., Davies, J., Morant, N., & Horowitz, M. (2023) · PLOS ONE · doi:10.1371/journal.pone.0282988 · Cited by 23
Self-citation
Metadata
- Authors
- Kendrick, T., Geraghty, A. W. A., Bowers, H., Stuart, B., Leydon, G., May, C., Yao, G., O’Brien, W., Glowacka, M., Holley, S., Williams, S., Zhu, S., Dewar-Haggart, R., Palmer, B., Bell, M., Collinson, S., Fry, I., Lewis, G., Griffiths, G., Gilbody, S., Moncrieff, J., Moore, M., Macleod, U., Little, P., & Dowrick, C.
- Venue
- Trials
- Published
- 2020-05-24
- Volume
- 21
- Issue
- 1
- Pages
- 419-419
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W3026525101
- Cited by
- 26
- References
- 18
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: REDUCE (Reviewing long-term antidepressant use by careful monitoring in everyday practice) internet and telephone support to people coming off long-term antidepressants: protocol for a randomised controlled trial. https://app.cochat.ai/papers/10.1186/s13063-020-04338-7
- The paper
- Kendrick, T., Geraghty, A. W. A., Bowers, H., Stuart, B., Leydon, G., May, C., Yao, G., O’Brien, W., Glowacka, M., Holley, S., Williams, S., Zhu, S., Dewar-Haggart, R., Palmer, B., Bell, M., Collinson, S., Fry, I., Lewis, G., Griffiths, G., . . . Dowrick, C. (2020). REDUCE (Reviewing long-term antidepressant use by careful monitoring in everyday practice) internet and telephone support to people coming off long-term antidepressants: protocol for a randomised controlled trial. Trials. https://doi.org/10.1186/s13063-020-04338-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.